OA12619A - Self-emulsifying formulations of cholesteryl estertransfer protein inhibitors. - Google Patents
Self-emulsifying formulations of cholesteryl estertransfer protein inhibitors. Download PDFInfo
- Publication number
- OA12619A OA12619A OA1200300317A OA1200300317A OA12619A OA 12619 A OA12619 A OA 12619A OA 1200300317 A OA1200300317 A OA 1200300317A OA 1200300317 A OA1200300317 A OA 1200300317A OA 12619 A OA12619 A OA 12619A
- Authority
- OA
- OAPI
- Prior art keywords
- substituted
- trifluoromethyl
- chain
- mono
- optionally
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
- Colloid Chemistry (AREA)
- Steroid Compounds (AREA)
- Peptides Or Proteins (AREA)
- Quinoline Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30002801P | 2001-06-21 | 2001-06-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA12619A true OA12619A (en) | 2006-06-12 |
Family
ID=23157363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| OA1200300317A OA12619A (en) | 2001-06-21 | 2002-05-03 | Self-emulsifying formulations of cholesteryl estertransfer protein inhibitors. |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US6962931B2 (hu) |
| EP (1) | EP1453544A2 (hu) |
| JP (1) | JP2005500314A (hu) |
| KR (1) | KR20040015746A (hu) |
| CN (1) | CN1635911A (hu) |
| AP (1) | AP2002002559A0 (hu) |
| AR (1) | AR034599A1 (hu) |
| BG (1) | BG108486A (hu) |
| BR (1) | BR0210505A (hu) |
| CA (1) | CA2455288A1 (hu) |
| CR (1) | CR7163A (hu) |
| CZ (1) | CZ20033341A3 (hu) |
| EA (1) | EA200301139A1 (hu) |
| EC (1) | ECSP034875A (hu) |
| EE (1) | EE200400024A (hu) |
| GT (1) | GT200200124A (hu) |
| HN (1) | HN2002000153A (hu) |
| HU (1) | HUP0400263A2 (hu) |
| IL (1) | IL158765A0 (hu) |
| IS (1) | IS7014A (hu) |
| MA (1) | MA27034A1 (hu) |
| MX (1) | MXPA04000014A (hu) |
| NO (1) | NO20035632L (hu) |
| OA (1) | OA12619A (hu) |
| PA (1) | PA8548601A1 (hu) |
| PE (1) | PE20030128A1 (hu) |
| PL (1) | PL368850A1 (hu) |
| SK (1) | SK15172003A3 (hu) |
| SV (1) | SV2003001103A (hu) |
| TN (1) | TNSN03139A1 (hu) |
| UY (1) | UY27344A1 (hu) |
| WO (1) | WO2003000295A2 (hu) |
| ZA (1) | ZA200308561B (hu) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL143604A0 (en) * | 1998-12-30 | 2002-04-21 | Dexcel Ltd | Dispersable concentrate for the delivery of cyclosporin |
| US7732404B2 (en) * | 1999-12-30 | 2010-06-08 | Dexcel Ltd | Pro-nanodispersion for the delivery of cyclosporin |
| JP4031232B2 (ja) * | 2001-11-09 | 2008-01-09 | カプスゲル・ジャパン株式会社 | 新規カプセル |
| ES2305434T3 (es) | 2002-02-01 | 2008-11-01 | Pfizer Products Inc. | Composiciones framaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas. |
| CA2478433C (en) * | 2002-03-01 | 2009-12-08 | Cesi Chemical, A Flotek Company | Composition and process for well cleaning |
| US20040175341A1 (en) * | 2003-03-04 | 2004-09-09 | Manning Monna Marie | Microemulsion for cosmetic or pharmaceutical use containing an active ingredient |
| JP2006520810A (ja) * | 2003-03-17 | 2006-09-14 | 日本たばこ産業株式会社 | Ｓ−［２−（［［１−（２−エチルブチル）シクロヘキシル］カルボニル］アミノ）フェニル］２−メチルプロパンチオエートの経口吸収性を増加させる方法 |
| CN101036636A (zh) * | 2003-03-17 | 2007-09-19 | 日本烟草产业株式会社 | 提高s－[2－([[1－(2－乙基丁基)环己基]羰基]氨基)苯基]－2－甲基丙硫代酸酯口服生物利用度的方法 |
| ES2377121T3 (es) * | 2003-03-17 | 2012-03-22 | Japan Tobacco Inc. | Composiciones farmacéuticas de inhibidores de CETP |
| TWI494102B (zh) * | 2003-05-02 | 2015-08-01 | Japan Tobacco Inc | 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合 |
| MXPA06001417A (es) * | 2003-08-04 | 2006-05-15 | Pfizer Prod Inc | Composiciones farmaceuticas de adsorbatos de farmacos amorfos y materiales que forman microfases lipofilas. |
| EP1670765A2 (en) * | 2003-09-30 | 2006-06-21 | Pfizer Products Inc. | Cetp inhibitors and metabolites thereof |
| DK1670768T3 (da) * | 2003-10-08 | 2009-11-09 | Lilly Co Eli | Forbindelser og fremgangsmåder til at behandle dyslipidæmi |
| US20050220866A1 (en) * | 2004-04-02 | 2005-10-06 | Dr. Reddy's Laboratories Limited | Novel capsule formulations of etoposide for oral use |
| WO2006069162A1 (en) | 2004-12-20 | 2006-06-29 | Reddy Us Therapeutics, Inc. | Novel heterocyclic compounds and their pharmaceutical compositions |
| KR101238525B1 (ko) | 2004-12-31 | 2013-02-28 | 레디 유에스 테라퓨틱스 인코포레이티드 | Ｃｅｔｐ 저해제로서의 신규 벤질아민 유도체 |
| US8604055B2 (en) | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
| WO2006085217A2 (en) * | 2005-02-08 | 2006-08-17 | Pfizer Products Inc. | Solid adsorbates of hydrophobic drugs |
| US7623458B2 (en) * | 2005-09-30 | 2009-11-24 | The Boeing Company | System and method for providing integrated services across cryptographic boundaries in a network |
| ATE516016T1 (de) | 2005-12-05 | 2011-07-15 | Merck Sharp & Dohme | Selbstemulgierende formulierungen von cetp- hemmern |
| WO2007076699A1 (fr) * | 2005-12-31 | 2007-07-12 | Tianjin Tasly Pharmaceutical Co. Ltd., China | Composition pharmaceutique contenant un extrait de chenopodium ambrosioides et son procédé de préparation et son application |
| JP2009542677A (ja) * | 2006-06-30 | 2009-12-03 | シェーリング コーポレイション | トロンビン受容体拮抗薬の固形製剤 |
| EP1961412A1 (en) * | 2006-12-27 | 2008-08-27 | LEK Pharmaceuticals D.D. | Self-microemulsifying drug delivery systems |
| US9222013B1 (en) | 2008-11-13 | 2015-12-29 | Cesi Chemical, Inc. | Water-in-oil microemulsions for oilfield applications |
| WO2010066593A1 (en) * | 2008-12-08 | 2010-06-17 | F. Hoffmann-La Roche Ag | Combined drug administration |
| US20100273730A1 (en) * | 2009-04-27 | 2010-10-28 | Innopharmax, Inc. | Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof |
| RU2012101214A (ru) | 2009-06-16 | 2013-07-27 | Пфайзер Инк. | Лекарственные формы апиксабана |
| CA2835912A1 (en) * | 2011-05-20 | 2012-11-29 | Aventis Pharmaceuticals Inc. | Pharmaceutical composition comprising fexofenadine |
| US9199967B2 (en) | 2011-08-18 | 2015-12-01 | Dr. Reddy's Laboratories Ltd. | Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors |
| CA2850022C (en) | 2011-09-27 | 2018-05-01 | Dr. Reddy's Laboratories, Ltd. | 5 - benzylaminomethyl - 6 - aminopyrazolo [3,4-b] pyridine derivatives as cholesteryl ester-transfer protein (cetp) inhibitors useful for the treatment of atherosclerosis |
| EP2768486B1 (en) * | 2011-10-21 | 2018-10-03 | First Tech International Limited | Tocotrienol compositions |
| DK2838970T3 (en) | 2012-04-15 | 2017-03-20 | Flotek Chemistry Llc | Density formulations for foam filling |
| US9200192B2 (en) | 2012-05-08 | 2015-12-01 | Cesi Chemical, Inc. | Compositions and methods for enhancement of production of liquid and gaseous hydrocarbons |
| US11407930B2 (en) | 2012-05-08 | 2022-08-09 | Flotek Chemistry, Llc | Compositions and methods for enhancement of production of liquid and gaseous hydrocarbons |
| US20160000799A1 (en) * | 2013-02-21 | 2016-01-07 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical compositions of cetp inhibitors |
| US10421707B2 (en) | 2013-03-14 | 2019-09-24 | Flotek Chemistry, Llc | Methods and compositions incorporating alkyl polyglycoside surfactant for use in oil and/or gas wells |
| US9321955B2 (en) | 2013-06-14 | 2016-04-26 | Flotek Chemistry, Llc | Methods and compositions for stimulating the production of hydrocarbons from subterranean formations |
| US11180690B2 (en) | 2013-03-14 | 2021-11-23 | Flotek Chemistry, Llc | Diluted microemulsions with low surface tensions |
| US9428683B2 (en) | 2013-03-14 | 2016-08-30 | Flotek Chemistry, Llc | Methods and compositions for stimulating the production of hydrocarbons from subterranean formations |
| US10000693B2 (en) | 2013-03-14 | 2018-06-19 | Flotek Chemistry, Llc | Methods and compositions for use in oil and/or gas wells |
| US10053619B2 (en) | 2013-03-14 | 2018-08-21 | Flotek Chemistry, Llc | Siloxane surfactant additives for oil and gas applications |
| US10577531B2 (en) | 2013-03-14 | 2020-03-03 | Flotek Chemistry, Llc | Polymers and emulsions for use in oil and/or gas wells |
| US10590332B2 (en) | 2013-03-14 | 2020-03-17 | Flotek Chemistry, Llc | Siloxane surfactant additives for oil and gas applications |
| US9868893B2 (en) | 2013-03-14 | 2018-01-16 | Flotek Chemistry, Llc | Methods and compositions for use in oil and/or gas wells |
| US9884988B2 (en) | 2013-03-14 | 2018-02-06 | Flotek Chemistry, Llc | Methods and compositions for use in oil and/or gas wells |
| US10941106B2 (en) | 2013-03-14 | 2021-03-09 | Flotek Chemistry, Llc | Methods and compositions incorporating alkyl polyglycoside surfactant for use in oil and/or gas wells |
| US10287483B2 (en) | 2013-03-14 | 2019-05-14 | Flotek Chemistry, Llc | Methods and compositions for use in oil and/or gas wells comprising a terpene alcohol |
| US10717919B2 (en) | 2013-03-14 | 2020-07-21 | Flotek Chemistry, Llc | Methods and compositions for use in oil and/or gas wells |
| US9068108B2 (en) | 2013-03-14 | 2015-06-30 | Cesi Chemical, Inc. | Methods and compositions for stimulating the production of hydrocarbons from subterranean formations |
| US11254856B2 (en) | 2013-03-14 | 2022-02-22 | Flotek Chemistry, Llc | Methods and compositions for use in oil and/or gas wells |
| US9464223B2 (en) | 2013-03-14 | 2016-10-11 | Flotek Chemistry, Llc | Methods and compositions for use in oil and/or gas wells |
| CN104706586A (zh) * | 2013-12-16 | 2015-06-17 | 天津迈迪瑞康生物医药科技有限公司 | 一种丁酸氯维地平脂肪乳浓缩液、其制备方法及用途 |
| CN104706587A (zh) * | 2013-12-16 | 2015-06-17 | 天津迈迪瑞康生物医药科技有限公司 | 一种依托咪酯脂肪乳浓缩液、其制备方法及用途 |
| CN104706689A (zh) * | 2013-12-16 | 2015-06-17 | 天津迈迪瑞康生物医药科技有限公司 | 一种鸦胆子油脂肪乳浓缩液、其制备方法及用途 |
| US9890625B2 (en) | 2014-02-28 | 2018-02-13 | Eclipse Ior Services, Llc | Systems and methods for the treatment of oil and/or gas wells with an obstruction material |
| US9890624B2 (en) | 2014-02-28 | 2018-02-13 | Eclipse Ior Services, Llc | Systems and methods for the treatment of oil and/or gas wells with a polymeric material |
| US9505970B2 (en) | 2014-05-14 | 2016-11-29 | Flotek Chemistry, Llc | Methods and compositions for use in oil and/or gas wells |
| US10294757B2 (en) | 2014-07-28 | 2019-05-21 | Flotek Chemistry, Llc | Methods and compositions related to gelled layers in oil and/or gas wells |
| TWI728959B (zh) | 2014-11-04 | 2021-06-01 | 因華生技製藥股份有限公司 | 不穩定或難溶藥物的口服投予 |
| CN104546710A (zh) * | 2014-12-20 | 2015-04-29 | 长沙佰顺生物科技有限公司 | 一种安塞曲匹纳米乳及其制备方法 |
| CN104490775A (zh) * | 2014-12-20 | 2015-04-08 | 长沙佰顺生物科技有限公司 | 一种安塞曲匹脂肪乳及其制备方法 |
| KR101590072B1 (ko) * | 2014-12-23 | 2016-01-29 | 한미약품 주식회사 | 두타스테라이드를 포함하는 자가유화 약물전달 시스템용 조성물 |
| EA038013B1 (ru) | 2015-05-28 | 2021-06-23 | Др. Редди'С Лабораториз Лтд. | Пероральная композиция целекоксиба для лечения боли |
| SG11201808949SA (en) | 2016-04-15 | 2018-11-29 | Novira Therapeutics Inc | Combinations and methods comprising a capsid assembly inhibitor |
| US10934472B2 (en) | 2017-08-18 | 2021-03-02 | Flotek Chemistry, Llc | Compositions comprising non-halogenated solvents for use in oil and/or gas wells and related methods |
| US11053433B2 (en) | 2017-12-01 | 2021-07-06 | Flotek Chemistry, Llc | Methods and compositions for stimulating the production of hydrocarbons from subterranean formations |
| AU2019235522A1 (en) | 2018-03-14 | 2020-09-03 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
| BR112021009967A2 (pt) * | 2018-11-26 | 2021-08-17 | Hepion Pharmaceuticals, Inc. | formulações farmacêuticas de análogos de ciclosporina |
| EA202192793A1 (ru) * | 2019-04-11 | 2022-01-12 | Ар.Пи. ШЕРЕР ТЕКНОЛОДЖИЗ, ЭлЭлСи | Композиция для пероральной доставки белков, пептидов и малых молекул со слабой проницаемостью |
| CN110252395B (zh) * | 2019-07-01 | 2020-10-16 | 湖北远大生命科学与技术有限责任公司 | 一种用于制备高纯度牛磺酸的催化剂及其应用 |
| US11104843B2 (en) | 2019-10-10 | 2021-08-31 | Flotek Chemistry, Llc | Well treatment compositions and methods comprising certain microemulsions and certain clay control additives exhibiting synergistic effect of enhancing clay swelling protection and persistency |
| FR3110852B1 (fr) | 2020-05-27 | 2024-03-15 | Centre Nat Rech Scient | Emulsions pour liberation controlee de medicaments |
| US11512243B2 (en) | 2020-10-23 | 2022-11-29 | Flotek Chemistry, Llc | Microemulsions comprising an alkyl propoxylated sulfate surfactant, and related methods |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI65914C (fi) * | 1978-03-07 | 1984-08-10 | Sandoz Ag | Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a |
| GB9208712D0 (en) | 1992-04-22 | 1992-06-10 | Sandoz Ltd | Pharmaceutical compositions containing cyclosporin derivates |
| AU2517095A (en) | 1994-05-19 | 1995-12-18 | R.P. Scherer International Corporation | Solutions of aryl or heteroaryl substituted alkanoic acids in lipophilic solvents and soft gelatin capsules containing such solutions |
| US5965160A (en) * | 1995-04-24 | 1999-10-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Self-emulsifiable formulation producing an oil-in-water emulsion |
| GB9608719D0 (en) | 1996-04-26 | 1996-07-03 | Scherer Ltd R P | Pharmaceutical compositions |
| US5993858A (en) * | 1996-06-14 | 1999-11-30 | Port Systems L.L.C. | Method and formulation for increasing the bioavailability of poorly water-soluble drugs |
| US5958876A (en) * | 1996-06-19 | 1999-09-28 | Novartis Ag | Cyclosporin-containing pharmaceutical compositions |
| PT1413297E (pt) | 1996-06-19 | 2008-07-28 | Novartis Ag | Preparações contendo ciclosporina |
| JP2894445B2 (ja) * | 1997-02-12 | 1999-05-24 | 日本たばこ産業株式会社 | Ｃｅｔｐ活性阻害剤として有効な化合物 |
| AU9297798A (en) * | 1997-09-16 | 1999-04-05 | G.D. Searle & Co. | Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity |
| DE19741399A1 (de) * | 1997-09-19 | 1999-03-25 | Bayer Ag | Tetrahydrochinoline |
| US6063762A (en) | 1997-12-05 | 2000-05-16 | Chong Kun Dang Corp. | Cyclosporin-containing microemulsion preconcentrate composition |
| AU3285499A (en) * | 1998-02-13 | 1999-08-30 | G.D. Searle & Co. | Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity |
| US6147090A (en) | 1998-09-17 | 2000-11-14 | Pfizer Inc. | 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| GT199900147A (es) * | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
| US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| US6140342A (en) * | 1998-09-17 | 2000-10-31 | Pfizer Inc. | Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines |
| CA2345108A1 (en) * | 1998-09-25 | 2000-04-06 | Monsanto Company | Substituted n-aliphatic-n-aromatic tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity |
| IL143604A0 (en) | 1998-12-30 | 2002-04-21 | Dexcel Ltd | Dispersable concentrate for the delivery of cyclosporin |
| CO5271716A1 (es) * | 1999-11-30 | 2003-04-30 | Pfizer Prod Inc | Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida |
| US6482862B1 (en) * | 1999-12-20 | 2002-11-19 | G.D. Searle & Co. | Method of using substituted N-benzyl-N-phenyl aminoalcohols for inhibiting cholesteryl ester transfer protein activity |
| US7115279B2 (en) * | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| CA2448864C (en) * | 2001-06-22 | 2008-04-22 | Pfizer Products Inc. | Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer |
| MXPA03011935A (es) * | 2001-06-22 | 2004-03-26 | Pfizer Prod Inc | Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco. |
| ATE444060T1 (de) * | 2001-06-22 | 2009-10-15 | Pfizer Prod Inc | Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren |
| EP1269994A3 (en) * | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
| ES2305434T3 (es) * | 2002-02-01 | 2008-11-01 | Pfizer Products Inc. | Composiciones framaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas. |
| CA2474835A1 (en) * | 2002-02-01 | 2003-08-07 | Pfizer Products Inc. | Immediate release dosage forms containing solid drug dispersions |
| US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
| ES2300628T3 (es) * | 2002-12-20 | 2008-06-16 | Pfizer Products Inc. | Formas de dosificacion que comprenden un inhibidor de cetp y un inhibidor de la hmg-coa reductasa. |
-
2002
- 2002-05-03 IL IL15876502A patent/IL158765A0/xx unknown
- 2002-05-03 MX MXPA04000014A patent/MXPA04000014A/es active IP Right Grant
- 2002-05-03 TN TNPCT/IB2002/001571A patent/TNSN03139A1/fr unknown
- 2002-05-03 HU HU0400263A patent/HUP0400263A2/hu unknown
- 2002-05-03 SK SK1517-2003A patent/SK15172003A3/sk not_active Application Discontinuation
- 2002-05-03 KR KR10-2003-7016651A patent/KR20040015746A/ko not_active Application Discontinuation
- 2002-05-03 CN CNA028124820A patent/CN1635911A/zh active Pending
- 2002-05-03 CA CA002455288A patent/CA2455288A1/en not_active Abandoned
- 2002-05-03 EE EEP200400024A patent/EE200400024A/xx unknown
- 2002-05-03 CZ CZ20033341A patent/CZ20033341A3/cs unknown
- 2002-05-03 WO PCT/IB2002/001571 patent/WO2003000295A2/en active Application Filing
- 2002-05-03 JP JP2003506937A patent/JP2005500314A/ja active Pending
- 2002-05-03 EP EP02732994A patent/EP1453544A2/en not_active Withdrawn
- 2002-05-03 PL PL02368850A patent/PL368850A1/xx not_active Application Discontinuation
- 2002-05-03 OA OA1200300317A patent/OA12619A/en unknown
- 2002-05-03 EA EA200301139A patent/EA200301139A1/ru unknown
- 2002-05-03 BR BR0210505-5A patent/BR0210505A/pt not_active IP Right Cessation
- 2002-06-19 PE PE2002000528A patent/PE20030128A1/es not_active Application Discontinuation
- 2002-06-19 AR ARP020102297A patent/AR034599A1/es unknown
- 2002-06-19 US US10/175,643 patent/US6962931B2/en not_active Expired - Fee Related
- 2002-06-19 GT GT200200124A patent/GT200200124A/es unknown
- 2002-06-20 HN HN2002000153A patent/HN2002000153A/es unknown
- 2002-06-20 PA PA20028548601A patent/PA8548601A1/es unknown
- 2002-06-20 UY UY27344A patent/UY27344A1/es not_active Application Discontinuation
- 2002-06-20 AP APAP/P/2002/002559A patent/AP2002002559A0/en unknown
- 2002-06-20 SV SV2002001103A patent/SV2003001103A/es not_active Application Discontinuation
-
2003
- 2003-10-31 IS IS7014A patent/IS7014A/is unknown
- 2003-11-03 ZA ZA200308561A patent/ZA200308561B/xx unknown
- 2003-11-24 CR CR7163A patent/CR7163A/es not_active Application Discontinuation
- 2003-12-03 EC EC2003004875A patent/ECSP034875A/es unknown
- 2003-12-10 MA MA27430A patent/MA27034A1/fr unknown
- 2003-12-17 NO NO20035632A patent/NO20035632L/no not_active Application Discontinuation
- 2003-12-22 BG BG108486A patent/BG108486A/bg unknown
-
2005
- 2005-09-08 US US11/222,908 patent/US20060014788A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| OA12619A (en) | Self-emulsifying formulations of cholesteryl estertransfer protein inhibitors. | |
| US20050038007A1 (en) | Dosage forms of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors | |
| EP2305217B1 (en) | Method for the preparation of pharmaceutical compositions comprising a solid amorphous dispersion of cholesteryl ester transfer protein inhibitors | |
| EP1581210B1 (en) | Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor | |
| EP1961419B1 (en) | Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor | |
| US20030198674A1 (en) | Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor | |
| JP6445591B2 (ja) | シロリムス及びその誘導体の複合体、それらの調製方法ならびにそれらを含有する医薬組成物 | |
| ZA200300869B (en) | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors. | |
| WO2004056396A1 (en) | DOSAGE FORMS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS WITH IMPROVED PERFORMANCE | |
| WO2004082676A1 (en) | Drug formulations having long and medium chain triglycerides | |
| AU2008345527A1 (en) | Novel taxoid-based compositions | |
| CA2425338C (en) | Compositions comprising modafinil compounds | |
| AU2002304366A1 (en) | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors | |
| KR100580577B1 (ko) | 자가 미세 유화형 약물 전달 시스템을 이용하는 소염 진통활성을 갖는 약제 조성물 | |
| AU2003201713A1 (en) | Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor |